Mark J. Osborn, Ph.D. - Publications

Affiliations: 
2009 Microbiology, Immunology and Cancer Biology University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Genetics

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kang E, Kim YM, Seo GH, Oh A, Yoon HM, Ra YS, Kim EK, Kim H, Heo SH, Kim GH, Osborn MJ, Tolar J, Yoo HW, Lee BH. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. Journal of Human Genetics. PMID 31776437 DOI: 10.1038/s10038-019-0695-0  0.68
2019 Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BS, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications. 10: 5222. PMID 31745080 DOI: 10.1038/s41467-019-13007-6  0.68
2019 Kim YM, Yum MS, Heo SH, Kim T, Jin HK, Bae JS, Seo GH, Oh A, Yoon HM, Lim HT, Kim HW, Ko TS, Lim HS, Osborn MJ, Tolar J, et al. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. Journal of Medical Genetics. PMID 31649052 DOI: 10.1136/jmedgenet-2019-106132  0.68
2019 Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, et al. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. Jci Insight. 4. PMID 31578305 DOI: 10.1172/jci.insight.127716  0.64
2019 Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, Xia L, Chen W, Eide CR, Webber BR, Wandall HH, Dabelsteen S, Blazar BR, Liu DR, Tolar J. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. The Journal of Investigative Dermatology. PMID 31437443 DOI: 10.1016/j.jid.2019.07.701  0.68
2018 McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, ... ... Osborn MJ, et al. The vimentin intermediate filament network restrains regulatory T-cell suppression of graft-versus-host disease. The Journal of Clinical Investigation. PMID 30106752 DOI: 10.1172/JCI95713  0.64
2018 Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, ... ... Osborn MJ, et al. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29735365 DOI: 10.1016/j.ymthe.2018.04.006  0.68
2018 Vanden Oever M, Twaroski K, Osborn MJ, Wagner JE, Tolar J. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. Pediatric Research. 83: 318-324. PMID 29593249 DOI: 10.1038/pr.2017.244  0.68
2018 Osborn MJ, Lees CJ, McElroy AN, Merkel SC, Eide CR, Mathews W, Feser CJ, Tschann M, McElmury RT, Webber BR, Kim CJ, Blazar BR, Tolar J. CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. International Journal of Molecular Sciences. 19. PMID 29565806 DOI: 10.3390/ijms19040946  0.68
2018 Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. International Journal of Molecular Sciences. 19. PMID 29364163 DOI: 10.3390/ijms19020340  0.68
2017 Webber BR, O'Connor KT, McElmurry RT, Durgin EN, Eide CR, Lees CJ, Riddle MJ, Mathews WE, Frank NY, Kluth MA, Ganss C, Moriarity BS, Frank MH, Osborn MJ, Tolar J. Rapid generation of Col7a1(-/-) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28892093 DOI: 10.1038/labinvest.2017.85  0.68
2017 Skvarova Kramarzova K, Osborn MJ, Webber BR, DeFeo AP, McElroy AN, Kim CJ, Tolar J. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. International Journal of Molecular Sciences. 18. PMID 28613254 DOI: 10.3390/ijms18061269  0.68
2017 Knipping F, Osborn MJ, Petri K, Tolar J, Glimm H, von Kalle C, Schmidt M, Gabriel R. Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification. Molecular Therapy. Methods & Clinical Development. 4: 213-224. PMID 28345006 DOI: 10.1016/j.omtm.2017.01.005  0.68
2016 Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, Xia L, Eide C, Lees CJ, McElmurry RT, Riddle MJ, Kim CJ, Patel DD, Blazar BR, Tolar J. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. Npj Regenerative Medicine. 1. PMID 28250968 DOI: 10.1038/npjregenmed.2016.14  0.68
2016 Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J, Braunlin EA. Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. Journal of Inherited Metabolic Disease. PMID 27743312 DOI: 10.1007/s10545-016-9988-z  0.68
2016 Osborn MJ, Belanto JJ, Tolar J, Voytas DF. Gene editing and its application for hematological diseases. International Journal of Hematology. 104: 18-28. PMID 27233509 DOI: 10.1007/s12185-016-2017-z  0.68
2016 Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, et al. Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 570-81. PMID 26502778 DOI: 10.1038/mt.2015.197  0.68
2016 Perdoni C, Osborn MJ, Tolar J. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa. Translational Research : the Journal of Laboratory and Clinical Medicine. 168: 50-8. PMID 26073463 DOI: 10.1016/j.trsl.2015.05.008  0.68
2015 Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 125: 3335-46. PMID 25814530 DOI: 10.1182/blood-2014-09-603357  0.64
2015 Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi anemia gene editing by the CRISPR/Cas9 system. Human Gene Therapy. 26: 114-26. PMID 25545896 DOI: 10.1089/hum.2014.111  0.68
2014 Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, Keene DR, Liu L, Osborn MJ, Lund TC, Blazar BR, Wagner JE. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. The Journal of Investigative Dermatology. 134: 1246-54. PMID 24317394 DOI: 10.1038/jid.2013.523  0.68
2013 Dietz WM, Skinner NE, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ, Hwu P, Chen ZY, Salazar AM, Ohlfest JR, Blazar BR, Pennell CA, Osborn MJ. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1526-35. PMID 23689601 DOI: 10.1038/mt.2013.85  0.64
2013 Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, et al. TALEN-based gene correction for epidermolysis bullosa. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1151-9. PMID 23546300 DOI: 10.1038/mt.2013.56  0.68
2013 Tolar J, Xia L, Lees CJ, Riddle M, McElroy A, Keene DR, Lund TC, Osborn MJ, Marinkovich MP, Blazar BR, Wagner JE. Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa. The Journal of Investigative Dermatology. 133: 562-5. PMID 22931927 DOI: 10.1038/jid.2012.278  0.68
2011 Osborn MJ, DeFeo AP, Blazar BR, Tolar J. Synthetic zinc finger nuclease design and rapid assembly. Human Gene Therapy. 22: 1155-65. PMID 21663559 DOI: 10.1089/hum.2011.072  0.68
2011 Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. The Journal of Investigative Dermatology. 131: 848-56. PMID 21124339 DOI: 10.1038/jid.2010.346  0.68
2011 Osborn MJ, McElmurry RT, Lees CJ, DeFeo AP, Chen ZY, Kay MA, Naldini L, Freeman G, Tolar J, Blazar BR. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 450-60. PMID 21081900 DOI: 10.1038/mt.2010.249  0.68
2011 Tolar J, Park IH, Xia L, Lees CJ, Peacock B, Webber B, McElmurry RT, Eide CR, Orchard PJ, Kyba M, Osborn MJ, Lund TC, Wagner JE, Daley GQ, Blazar BR. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. 117: 839-47. PMID 21037085 DOI: 10.1182/blood-2010-05-287607  0.68
2010 Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. The New England Journal of Medicine. 363: 629-39. PMID 20818854 DOI: 10.1056/NEJMoa0910501  0.68
2010 Kelly RM, Goren EM, Taylor PA, Mueller SN, Stefanski HE, Osborn MJ, Scott HS, Komarova EA, Gudkov AV, Holländer GA, Blazar BR. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood. 115: 1088-97. PMID 19965631 DOI: 10.1182/blood-2009-05-223198  0.64
2008 Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. Targeting of the CNS in MPS-IH Using a Nonviral Transferrin-α-l-iduronidase Fusion Gene Product. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1459-1466. PMID 28182871 DOI: 10.1038/mt.2008.119  0.68
2008 Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1459-66. PMID 18523448 DOI: 10.1038/mt.2008.119  0.68
2007 Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (Dayton, Ohio). 25: 371-9. PMID 17038675 DOI: 10.1634/stemcells.2005-0620  0.68
2005 Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell SK, Vignali DA, Ryan MD, Wilber AC, McIvor RS, Tolar J, Blazar BR. A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 569-74. PMID 15964244 DOI: 10.1016/j.ymthe.2005.04.013  0.68
Show low-probability matches.